Core Viewpoint - Hongbo Pharmaceutical's stock increased by 5.06% to 30.94 CNY per share, with a total market capitalization of 4.319 billion CNY as of November 24 [1] Company Overview - Hongbo Pharmaceutical, established on December 14, 2007, is located in the Pudong New Area of Shanghai and was listed on November 1, 2022 [1] - The company's main business includes drug discovery, pharmaceutical process research and development, and commercial production of raw material intermediates [1] - Revenue composition: Drug discovery accounts for 52.67%, commercial production 35.00%, process research and development 8.10%, and other activities 4.23% [1] Shareholder Information - Changcheng Fund's Changcheng Consumption Value Mixed A (200006) is among the top ten circulating shareholders of Hongbo Pharmaceutical, holding 1.6009 million shares, unchanged from the previous period, representing 2.08% of circulating shares [2] - The fund has an estimated floating profit of approximately 2.3854 million CNY as of today [2] Fund Performance - Changcheng Consumption Value Mixed A (200006) was established on April 6, 2006, with a current scale of 516 million CNY [2] - Year-to-date return is 14.39%, ranking 4459 out of 8209 in its category; one-year return is 6.92%, ranking 5776 out of 8129; and since inception, the return is 232.84% [2] Fund Manager Information - The fund manager of Changcheng Consumption Value Mixed A is Long Yufei, who has been in the position for 8 years and 40 days [3] - The total asset size of the fund is 843 million CNY, with the best return during the tenure being 61.42% and the worst return being -8.9% [3] Fund Holdings - Changcheng Consumption Value Mixed A (200006) has Hongbo Pharmaceutical as its sixth-largest holding, with 1.6009 million shares, accounting for 6.61% of the fund's net value [4] - The estimated floating profit for the fund from this holding is approximately 2.3854 million CNY [4]
泓博医药股价涨5.06%，长城基金旗下1只基金重仓，持有160.09万股浮盈赚取238.54万元